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Abstract
Background: Dengue viruses (DENV) attach to the host cell surface and subsequently enter the
cell by receptor-mediated endocytosis. Several primary and low affinity co-receptors for this
flavivirus have been identified. However, the presence of these binding molecules on the cell
surface does not necessarily render the cell susceptible to infection. Determination of which of
them serve as bona fide receptors for this virus in the vector may be relevant to treating DENV
infection and in designing control strategies.
Results: (1) Overlay protein binding assay showed two proteins with molecular masses of 80 and
67 kDa (R80 and R67). (2) Specific antibodies against these two proteins inhibited cell binding and
infection. (3) Both proteins were bound by all four serotypes of dengue virus. (4) R80 and R67 were
purified by affinity chromatography from Ae. aegypti mosquito midguts and from Ae albopictus C6/
36 cells. (5) In addition, a protein with molecular mass of 57 kDa was purified by affinity
chromatography from the midgut extracts. (6) R80 and R67 from radiolabeled surface membrane
proteins of C6/36 cells were immunoprecipitated by antibodies against Ae. aegypti midgut.
Conclusion: Our results strongly suggest that R67 and R80 are receptors for the four serotypes
of dengue virus in the midgut cells of Ae. aegypti and in C6/36 Ae. albopictus cells.
Background
Dengue (DEN) is distributed worldwide in tropical and
subtropical countries including Mexico and the USA and
is the most common vector-borne viral disease in
humans. Infection ranges from asymptomatic or mild
self-limited illness (dengue fever, DF) to a severe disease
with spontaneous hemorrhaging (dengue hemorrhagic
fever, DHF), or, most seriously, to DEN shock syndrome
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DEN infections with 500,000 cases of DHF and 12,000
deaths occur each year [1]. In the years 2002 to 2004,
23,826 cases of DEN and 5,557 of DHF were reported in
Mexico [2].
The Dengue virus (family Flaviviridae, genus Flavivirus,
species Dengue virus) infects mammalian [3] and vector
cells. Neutralizing antibodies facilitate the binding and
penetration of DENV into human macrophages; the virus-
antibody complex binds Fc receptors [4]. This mechanism
does not explain virus entry in primary infections or in
cells with non-Fc receptors. Transmission electron micro-
scopy shows that DEN viruses must attach to the cells
[5,6], suggesting that the cells must have virus receptor(s)
on their surfaces to be susceptible to infection. Proteins
[7-12], heparan sulfates [13], LPS/CD14-associated bind-
ing proteins [14] and other glycoproteins [15] have been
proposed as cellular receptors for DENV. In addition, DC-
SIGN [16-18] has been suggested as a mediator of DENV
infection in dendritic cells and could participate in bind-
ing large numbers of other viruses such as HIV-1, Ebola
and CytoMV to host cell surfaces [19].
In C6/36 cells, two major polypeptides have been
described with apparent molecular weights of 67 and 80
kDa, which bind to DEN virus serotype 2 (DENV2) [9].
The mechanism by which the virus enters mosquito cells
is unknown. The presence of receptor(s) on the surface
does not necessarily render a cell susceptible to infection.
In natural infection, DENV is first deposited in the mos-
quito vector and then in a human host bitten by the vector
during a blood meal. Therefore, it is necessary to study
receptors in the mosquito midgut (MG) to determine
which binding proteins serve as true virus receptors; they
may be relevant to treating DEN infection and in design-
ing control strategies. This is especially important because
mosquitoes differ in their susceptibilities to infection,
resulting in different vector competences [20-22].
The present study shows that the proteins R80 and R67 are
the putative receptors in the MG of Ae. aegypti. Moreover,
proteins with the same apparent molecular weights were
purified by DENV2 affinity chromatography from the MG
of this mosquito and from C6/36 cells. In addition, a pro-
tein with molecular weight of 57 kDa was also purified
from mosquito MG extracts by affinity chromatography.
Immunoprecipitation of radiolabeled membranes using
Ae. aegypti anti-MG antibodies showed that R80 and R67
are contained in mosquito cell membranes. Furthermore,
the four serotypes of DENV recognized the same proteins
on Ae. aegypti and C6/36 cells.
Results
Identification and purification of the putative DENV2 
receptors in Ae. aegypti midgut by the virus overlay protein 
binding assay
Mosquito MG proteins were extracted with 0.05% of Tri-
ton X-100, separated by SDS-PAGE, blotted on to a PVDF
membrane and incubated with biotinylated DENV2 virus
to identify the putative receptors. Two prominent
polypeptides with apparent molecular masses of 67 and
80 kDa were observed (Figure 1, panel A, lane 1). The neg-
ative control without virus showed no bands (data not
shown).
To purify the putative receptors, DENV2 affinity chroma-
tography was performed by passing cell membrane pro-
teins from C6/36 cells from Ae. albopictus (Figure 1, panel
A, lane 2) or MG proteins from Ae. aegypti through a
DENV2-Sepharose™ 4B column. Representative patterns
(from 8 experiments) of C6/36 cell membrane or midgut
proteins retained and eluted by the column (EP) are
shown in Figure 1 panel A, lane 3, and Figure 1 panel B,
respectively. Two major proteins with molecular masses
of 67 (R67) and 80 (R80) kDa were observed. Figure 1A
lane 2 shows the total protein pattern of C6/36 cells. MG
proteins eluted from the column showed an additional
band with apparent molecular weight of 57 kDa (Figure 1,
panel B). Fraction 2 showed the 80 kDa protein (Figure 1,
panel B, lane 2).
Immunoprecipitation of the putative receptors from C6/36 
cell apical surfaces
To confirm that the putative receptors in Ae. aegypti MG
epithelial cells are similar to those in Ae. albopictus C6/36
cells, the apical surfaces of C6/36 cells were labeled with
125I and precipitated with anti-C6/36 cell membrane and
anti-MG antibodies. Antibody specificity was tested by
immunoblotting (Figure 2, panel A, lanes 2, 4). Proteins
with apparent molecular weights over 180 kDa were rec-
ognized. The negative control with pre-immune serum
showed no bands (Figure 2, lanes 3 and 5).
Labeled proteins from the apical surfaces of C6/36 cells
(Figure 3, lane 1) precipitated by polyclonal antibodies
against Ae. aegypti MG (Figure 3, lane 2) or C6/36 cell
membranes (Figure 3, lane 3–4) were separated by 10%
SDS-PAGE. The immunoprecipitated labeled proteins had
molecular masses of 80 and 67 kDa. The labeled proteins
were not precipitated by an unrelated antibody, anti-actin
(Figure 3, lane 5).
Apical cell surface proteins bound the four serotypes of 
DEN virus
To determine whether different serotypes of DENV recog-
nized the same receptors, labeled apical cell surface pro-
teins from C6/36 cells were incubated with DENV1,Page 2 of 10
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tively) and precipitated by incubation with antibodies
against each DENV serotype. All four serotypes led to the
immunoprecipitation of proteins with molecular masses
of 80 and 67 kDa (Figure 3, lanes 7–10). Labeled C6/36
apical membrane proteins were precipitated by anti-EP
antibodies as a positive control (Figure 3, lane 11). The
control without DEN virus showed no polypeptides (Fig-
ure 3, lane 6).
Polyclonal antibody-mediated blocking of DENV2 binding 
and infection of C6/36 cells
The specificities of anti-EP, anti-R80 and anti-R67 pre-
pared to test inhibition of DEN virus binding and infec-
tion were assessed by immunoblotting (Figure 4) and
immunofluorescence (Figure 5) as described in the meth-
ods section. Anti-EP recognized two polypeptides with
molecular masses of 80 and 67 kDa (Figure 4, lane 2) and
anti-R80 and anti-R67 recognized polypeptides of 80 (Fig-
ure 4, lane 3) and 67 kDa (Figure 4, lane 4), respectively.
Pre-immune mouse serum recognized no polypeptides
(Figure 4, lane 1).
There was no immunofluorescence staining when C6/36
cells were incubated with pre-immune serum (Figure 5A).
In contrast, anti-membrane, anti-MG, anti-EP, anti-R67
and anti-R80 antibodies all stained the C6/36 membranes
(Figure 5B–F, respectively). Anti-R80 also stained the
cytoplasm (Figure 5F).
In order to test antibody blocking of DENV binding, C6/
36 cell monolayers were incubated with anti-EP, anti-R67,
anti-R80 or anti-MG antibodies or pre-immune serum,
then with 125I- DEN2 virus as described in the methods
section (Figure 6). Anti-EP, anti-R67 and anti-R80
VOPBA and DENV2 affinity chromatography of the virus dengue receptorsFigure 1
VOPBA and DENV2 affinity chromatography of the virus dengue receptors. Proteins from Aedes aegypti MGs were 
extracted with 0.05% Triton X-100, separated by 10% SDS-PAGE and blotted on to a PVDF membrane. The putative recep-
tors were revealed after incubation with DEN2 virus and peroxidase-labeled goat anti-mouse antibody (panel A, lane 1) as 
described in the methods section. Receptors were purified from C6/36 cell membranes (panel A, lane 3) or MG (fractions 1 
and 2, panel B) by DENV2 affinity chromatography using a DEN2-Sepharose™ 4B column as described in the methods section. 
The apparent molecular weights of these proteins are shown on the right side of panel A and on the left side of panel B. Pro-
teins separated by SDS-PAGE were silver stained. The protein pattern of total C6/36 membranes is shown in panel A lane 2. 
Molecular weight markers are shown on the left side in panel A and on the right side in panel B.Page 3 of 10
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ited by 70% when anti-MG was diluted 1:10 (Figure 6).
To test the inhibition of DENV2 infection by the specific
anti-receptor antibodies, C6/36 cell monolayers were
incubated separately for 1 h in media containing pre-
immune serum, anti-EP, anti-R67 or anti-R80 diluted
1:10 or 1:50, before being infected with DENV2. Infection
was allowed to proceed for 8 days and the amount of
infectious virus was determined by viral plaque assays in
LLC-MK2 cells (Figure 7). Maximal inhibition of infection
was obtained with anti-EP and anti-R67 diluted 1:10 (Fig-
ure 7). These antibodies inhibited DEN 2 replication in
the C6/36 cells nearly 1000-fold. Anti-R80 showed a rela-
tively minor inhibitory effect of approximately 100-fold.
Anti-EP, anti-R67 or anti-R80 diluted 1:50, and pre-
immune serum, did not inhibit DEN2 replication in these
cells.
Discussion
When a mosquito takes a viremic blood meal, virions
interact with receptors on the midgut epithelial cells and
penetrate and infect them. Arbovirus blocked at early
stages of midgut infection is considered a midgut infec-
tion barrier (MIB). A midgut escape barrier (MEB) is con-
sidered when infectious virions do not disseminate to
hemoceles, or disseminate but do not infect secondary tar-
get organs.
Most studies of flavivirus vector competence in Ae. aegypti
indicate that MIB is a major determinant of transmission
[23-25] and shows wide variation both among and within
Ae. aegypti populations for flaviviruses including DENV
[20,22,25]. Moreover, Ae. aegypti MG is generally consid-
ered the best candidate tissue for disrupting the virus life
cycle within the mosquito because it is the earliest inter-
face between insect and virus (see above). This strongly
suggests that DENV attachment to MG epithelial cell
receptors is critical for understanding the initial virus-vec-
tor interactions and will help to explain MIBs to DENV
infection and variations in vector competence. Further-
more, we would expect that virus serotype and genotype
would influence virus attachment to midgut receptors.
Thus, identification of viral receptors in the MG represents
a critical step in understanding vector competence and
designing possible targets for preventing viral entry to
cells and therefore inhibiting the infection. Feasible
approaches to intervention are monoclonal antibodies
blocking the receptor, and synthetic peptides mimicking
the viral receptor and thus competing with the host recep-
tor for virus attachment. This will allow novel strategies
for the control and prevention of DEN to be developed.
Published data have shown that the viral E protein is
involved in target cell recognition [6,26,27]. Recent struc-
tural and genetic evidence [28,29] suggests that the prM/
M stem-anchor region is also likely to play a role in virion
entry to cells. Purification by DENV 2 affinity chromatog-
raphy using native virus is a novel approach to obtaining
the putative protein receptors for DENV.
Several authors using the overlay assay have identified
polypeptides with molecular masses of 27, 45, 67 and 87
in macrophages [8], 40 and 70 in myelomonocytes [30],
45 and 72 kDa in B and T cells from humans [31], and two
heparan sulfate containing cell-surface binding proteins
resolving at 19 and 37 kDa in hepatocytes [32]. The data
in the present paper strongly support the view that the 67
and 80 kDa proteins are receptors for DENV 1, 2, 3 and 4
in MG cells from Aedes aegypti. Furthermore, we have puri-
fied these proteins for the first time from both Ae. albopic-
tus C6/36 cells and Ae. aegypti MGs using DENV2 affinity
chromatography; we also generated specific antibodies
against them, which inhibited binding and infection of
cultured cells by DENV 2. These results contrast with those
of Yazi-Mendoza et al. [33], who showed that DENV 4
binds to a 45 kDa protein in mosquito tissues. The results
in Figure 2 clearly demonstrate that DENV 4 recognizes
R67 and R80 in C6/36 cell membranes. A plausible expla-
Immunoblots of C6/36 total extractsFigure 2
Immunoblots of C6/36 total extracts. Extracts of C6/36 
cells (lanes 2, 3) or MG (lanes 4, 5) were subjected to 10% 
SDS-PAGE, blotted on to nitrocellulose and probed with 
anti-C6/36 membrane proteins (lane 2), pre-immune serum 
(lane 3), anti-MG (lane 4) or pre-immune serum (lane 5).Page 4 of 10
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extracts for their VOPBA, while our results were obtained
from plasma membranes, although viruses are known to
have several receptors [7]. In any event, further experi-
ments are needed to settle the point. Interestingly, Jindad-
amrongwech & Smith [7] found a serotype-specific
heterogeneity among DENV binding proteins on HepG2
human Liver cells. It is therefore possible that different
cell lines have different specificities for virus serotypes.
The specific antibodies against R67 and R80 inhibited
radiolabeled DEN virus binding and the highest inhibi-
tion was observed with anti-MG antibodies, suggesting
that other cell membrane molecules may participate in
virus binding. Candidates include non-sialic acid carbo-
hydrates, since we previously showed that sialic acid does
not participate in virus binding [9]. In agreement with our
results, Zieler et al. [29] failed to detect sialic acid in Ae.
aegypti MG. More recently, Thaisomboonsuk et al. [34]
reported the inability of neuroaminidase to inhibit DEN-
2 virus binding to insect cells.
As we mentioned earlier, DC-SIGN has also been reported
as a functional receptor on human dendritic cells [15,16]
for DENV and other flaviviruses. Further studies are
needed to determine the involvement of DC-SIGN as
receptor in DENV infection in Ae. aegypti mosquitoes.
Collectively, the results corroborate the notion that DENV
utilizes multiple cell surface molecules for binding to and
infection of target cells, some of which may be common
to all cells and shared among several viruses [6]. Interest-
ingly, Sakoonwtanyoo et al. [12] suggested that one of
these protein receptors for DENV 2, 3 and 4 may be a lam-
inin-binding protein with an apparent mass of 50 kDa.
Although we failed to detect a protein with this molecular
mass, this does not eliminate the possibility.
In summary, specific membrane molecules are required
for DENV binding and the nature of these molecules
seems to depend on cell type. Interestingly, our results
show that R67 and R80 are the putative receptors in the
MG of Ae. aegypti mosquitoes, the principal DENV vector
Immunoprecipitation of labeled membrane proteinsFigure 3
Immunoprecipitation of labeled membrane proteins. Proteins from C6/36 cell apical surfaces radiolabeled with 125I 
(lane 1) were immunoprecipitated with polyclonal anti-MG (lane 2) or anti-membrane (lane 3 and 4) and separated by 10% 
SDS-PAGE. The molecular weights of the immunoprecipitated proteins are shown on the left side. A negative control using an 
unrelated antibody (anti-actin) is shown in lane 5. Labeled apical cell surface proteins recognized by DEN1 (lane 7), DEN2 (lane 
8), DEN3 (lane 9) and DEN4 (lane 10) were immunoprecipitated with specific anti-DENV as described in the methods section. 
A control without DEN virus was included (lane 6). 125I-labeled proteins immunoprecipitated by anti-EP were used as a positive 
control (lane 11). All proteins were separated by 10% SDS-PAGE and labeled proteins were detected by autoradiography. The 
molecular weights of these proteins are shown on the right side. Molecular weight markers are shown on the left side.Page 5 of 10
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these receptors are specific for all four serotypes of DENV.
Conclusion
This paper documents for the first time that the proteins
R67 and R80 are putative receptors for dengue virus in the
midgut of Ae. aegypti and in Ae. albopictus C6/36 cells,
since specific antibodies against these proteins inhibited
the binding and cytopathic effects of the virus. Further-
more, we have shown that these receptors are specific for
all four serotypes of DENV.
Methods
Mosquito culture
A. aegypti mosquitoes collected as larvae in Monterrey,
Mexico were laboratory-reared and maintained at 28 ±
2°C and 80% RH under a 12:12 h (L:D) photoperiod
using standard mosquito-rearing procedures [35]. After
day 4, adult MGs were dissected and stored at -80°C until
use.
DENV infection cells
Ae. albopictus clone C6/36 cells were grown at 28°C as pre-
viously described [36]. After 18 h of culture, the cells (2 ×
106/100 mm plate) were infected with 0.2 ml DENV2
inoculum with an input MOI of 600 PFU per plate and
incubated at 28°C for 10 days.
Virus purification
The flaviviruses used in this study were: DENV1, strain
Hawaii; DENV2, strain New Guinea C (NGC); DENV3,
strain H-87; and DENV4, strain H-341. They were
obtained from Dr. D. J. Gubler (Division of Vector-borne
Infectious Diseases, Centers for Disease Control, Fort Col-
lins, CO, USA) and kindly provided by Dr. Blanca Ruiz
(Biomedicas, UNAM).
Virus passage in Vero cells was clarified from cell culture
supernatants. Viruses were concentrated and purified as
described by Putnak et al. [37]. Titers of virus stocks made
in LLC-MK2 cells [38] were 8 × 108 PFU/ml for each DENV
strain. Control antigens harvested from uninfected Vero
cells were prepared in the same manner.
The purified viruses were iodinated using 1 mCi of 125I
(Amersham Pharmacia Biotech) as described elsewhere
[39]. The specific activity was 4.7 × 109 cpm/mg of pro-
tein.
Biotinylation was performed as described previously [9].
The viral pellet was stored at -70°C until use.
Membrane preparation
C6/36 cell membranes were prepared essentially as
described elsewhere [40] by scraping the cells from con-
fluent plates in the presence of PBS. This procedure has
been described in detail for C6/36 cells [9]. Labeled mem-
brane proteins were identified at the 20% interface of the
gradient and verified by SDS-PAGE.
DENV2 affinity chromatography
DEN2 viruses (8 × 108 PFU/ml) were bound covalently to
1 g of CNBr-activated Sepharose™ 4B as recommended by
the manufacturer (Amersham Biosciences). The DENV2-
Sepharose™ column was stored in 0.002% sodium azide
at 4°C until use.
The protein extract was obtained by homogenizing MGs
(300/ml) in buffer E (50 mM Tris-HCl, pH 7.2, 1 mM
EDTA, 0.05% v/v Triton X-100) containing P 8340 pro-
tease inhibitor cocktail from Sigma. To obtain the soluble
proteins, the homogenate was centrifuged for 10 min at
7245 × g at 4°C.
Immunoblotting of total C6/36 extractsFigure 4
Immunoblotting of total C6/36 extracts. Extracts from 
C6/36 cells treated as in Figure 2 were tested with pre-
immune mouse serum (lane 1), anti-EP (lane 2), anti-R80 
(lane 3) or anti-R67 (lane 4). Molecular weight markers are 
shown on the left side and the proteins detected by the anti-
bodies on the right side.Page 6 of 10
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branes [4,9], was applied to a DENV2-Sepharose™ 4B col-
umn (1 ml) equilibrated in buffer E and washed with the
same buffer. The DENV2-binding proteins were eluted
with buffer E containing 0.5 M NaCl. Fractions of 0.5 ml
were collected, and the protein content was monitored by
the Bradford method [41] and analyzed by polyacryla-
mide gel electrophoresis in the presence of sodium
dodecyl sulfate on 10% gels [42]. The eluted proteins (EP)
were stored at -70°C.
Radiolabeling of C6/36 cell membrane proteins
Proteins from the apical surfaces of confluent monolayers
were iodinated by the lactoperoxidase method [39].
Labeled membrane proteins (specific activity 1.4 ×
106cpm/mg) in buffer E were used immediately or stored
at -70°C.
Antibodies
Monoclonal anti-DENV2 antibodies were obtained from
murine hybridomas (HB-46) from ATCC. Anti-DENV1,
DENV3 and DENV4 were kindly provided by Dr. Garry
Clark from CDC-Puerto Rico.
To obtain specific anti-R80 and anti-R67, proteins
retained by the DENV2-Sepharose™ 4B column were sep-
arated by 10% SDS-PAGE. After silver staining, each of the
two main protein species (R80, R67) was excised from the
gel, cut in small pieces, suspended in PBS and mixed with
an equal volume of Titer-Max adjuvant (CyTRx Corpora-
tion) to immunize two groups of BALB/c mice. Pre-
immune sera were obtained before immunization. Pro-
teins eluted (EP) from the DENV2 affinity column were
used to obtain specific polyclonal antibodies. A total of 10
μg of this protein was used to immunize the mice. MG
extracts (100 μg), or C6/36 cell membrane extracts (50
μg), were also used to immunize mice [9]. After fifteen
days, the mice received a booster; they were bled after
thirty days. Sera were stored at -70°C until use. Antibody
specificity was tested by ELISA and immunofluorescence.
Negative controls using pre-immune sera were included
in all assays.
Immunofluorescence microscopy of C6/36 cellsFigure 5
Immunofluorescence microscopy of C6/36 cells. Cell monolayers were stained with pre-immune serum (A), anti-cell 
membrane (B), anti-MG (C), anti-EP (D), anti-R67 (E) and anti-R80 (F) and then incubated with fluorescein-conjugated goat 
anti-mouse antibodies.Page 7 of 10
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C6/36 cells (1.5 × 104) were cultured overnight in 96-well
plates as described above. For binding assays, the cells
were incubated for 60 min at 4°C with pre-immune
serum, anti-EP, anti-R80, anti-R67 or anti-MG diluted
1:10 or 1:1000 in serum-free medium. Other cells were
left untreated. 125I-DENV of each serotype was added (600
PFU/well) and incubated for 30 min at 4°C. After washing
to remove non-bound labeled virus, cells containing the
bound virus were solubilized in 3% SDS and the radioac-
tivity was counted. For infection assays, cells were incu-
bated for 60 min with pre-immune serum, anti-EP, anti-
R80 or anti-R67 diluted 1:10 or 1:50 at 28°C and then
DENV serotype 2 was added (600 PFU/well) followed by
incubation for 30 min at 4°C. After washing, fresh culture
medium was added and the cells were incubated for 8
days. The viral titer was determined in each supernatant
by viral plaque assay in LLC-MK2 cells [43]. Four wells
were assessed for each experimental condition.
Immunofluorescence
C6/36 cell monolayers were stained as previously
described [9]. Pre-immune sera as well as each of the pol-
yclonal antibodies (anti-R80, anti-R67 and anti-MG) were
diluted 1:100 and incubated overnight at 4°C. After wash-
ing with PBS, the cells were incubated with fluorescein-
conjugated goat anti-mouse (1:500) antibodies (Hyclone
Laboratories, Inc., Utah). After further washing, they were
mounted in 50% glycerol and observed by fluorescence
microscopy.
Electrophoretic blotting
Proteins were electrophoresed in 10% SDS-PAGE [42]
and transferred to nitrocellulose paper [44]. Membranes
were incubated with anti-EP, anti-R80, anti-R67 or anti-
MG diluted 1:50. The goat anti/mouse IgG second anti-
body was conjugated to alkaline phosphatase and color
development was measured as recommended by the man-
ufacturer (Zymed Laboratories).
Virus overlay protein binding assay (VOPBA)
Mosquito MG proteins were separated by 10% SDS-PAGE
as described above and blotted on to PVDF membranes
(BioRad) by Towbin's technique [44]. The procedure was
followed as previously described [9] with some modifica-
tions. Briefly, the electrophoretic blots were incubated
overnight with unlabeled virus, washed with PBS and
incubated overnight with monoclonal anti-flavivirus
(diluted 1:100) at 4°C. After washing with PBS, they were
incubated for 2 h at room temperature with peroxidase-
labeled goat anti-mouse (Kirkegaarde Perry Laboratories,
USA) diluted 1:1000 in 5% skimmed milk in PBS. Finally,
they were washed with PBS, and reactive proteins were vis-
ualized by developing with the chromogenic substrate 4-
Inhibition of DENV2 infection by specific antibodiesFigure 7
Inhibition of DENV2 infection by specific antibodies. 
C6/36 cell monolayers were incubated separately in the pres-
ence of pre-immune serum, anti-EP, anti-R67 or anti-R80 at 
28°C for 60 min and then DENV serotype 2 was added (600 
PFU/well) and incubated for 30 min at 4°C. After washing, 
fresh culture medium was added and the cells were incu-
bated for 8 days. Pre-immune serum and antibodies were 
diluted 1:10 and 1:50. Viral titers in the supernatants were 
determined by viral plaque assay in LLC-MK2 cells. The 
experiments were repeated at least 3 times in quadruplicate.
Blocking of DEN-2 virus binding by specific antibodiesFigure 6
Blocking of DEN-2 virus binding by specific antibod-
ies. C6/36 cell monolayers were incubated with 1:10 or 
1:1000 diluted pre-immune serum (PI), anti-EP, anti-R67, 
anti-R80 or anti-MG. To assay the binding of radiolabeled 
virus, cells were dissolved in 3% SDS in all experiments. The 
total [125I]DENV2 virus bound was 5,286 ± 300 cpm. The 
experiments were repeated at least 3 times in quadruplicate.Page 8 of 10
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stopped after 1 h by washing with water.
Receptor-virus immunoprecipitation
Radiolabeled cell membrane proteins (5 μg) solubilized
in buffer E containing protease inhibitors (see above)
were incubated for 2 h at 37°C with 10 μl of each DENV
serotype (6.0 × 106 PFU/ml) and anti-DENV 1, 2, 3 or 4
antibodies diluted 1:100. The mixture was centrifuged at
5,000 × g for 15 min and washed twice with PBS. The
supernatant was discarded and the proteins from the pel-
let were suspended in SDS gel-loading buffer and sepa-
rated by 10% SDS-PAGE. Labeled polypeptides were
detected by autoradiography [45]. Negative controls were
included by incubating the same preparations with anti-
actin, an unrelated antibody.
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